Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.
Joyce F LiuMark F BradyUrsula A MatulonisAustin MillerElise C KohnElizabeth M SwisherDavid CellaWilliam P TewNoelle G ClovenCarolyn Y MullerDavid P BenderRichard G MooreDavid P MichelinSteven E WaggonerMelissa A GellerKeiichi FujiwaraStacy D D'AndreMichael CarneyAngeles A SecordKatherine M MoxleyMichael A BookmanPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
mutation, both olaparib and olaparib/cediranib had significant clinical activity.